What might a Trump administration mean for the Biosecure Act?

It’s still likely U.S. biotechs and pharmas will have to cut ties with key Chinese partners — it’s just a matter of when.  

By Amy Baxter • Nov. 20, 2024

What is a ‘cure,’ really? AbbVie’s Humira creator leaps into the next phase of medicine

AbbVie’s head of R&D cures has lofty ambitions to end diseases like HIV through a community of researchers that work as one.

By Michael Gibney • Nov. 19, 2024

Explore the Trendline➔

Commercialization, marketing and social media

As the pharma industry stares down a historic patent cliff, macroeconomic headwinds and challenging R&D costs for increasingly complex medicines, nailing the launch of new medicines has become increasingly critical. 

By PharmaVoice staff

Why Merck rolled the dice on an ‘unbelievable’ early-stage brain cancer drug

Merck’s acquisition of Modifi Biosciences bucks common M&A trends in pharma. 

By Kelly Bilodeau • Nov. 18, 2024

The first MASH drug could open the door for others — including GLP-1s

With only one approved drug on the market, companies like Inventiva Pharma are advancing MASH drugs and seeking a competitive edge.

By Amy Baxter • Nov. 18, 2024

Where are they now? 4 biotechs that soared then crashed during the pandemic

How Novavax and others have restructured and trudged forward after their COVID-era high.

By Meagan Parrish • Nov. 15, 2024

Left to clean up after ‘pharma bro’ Shkreli’s arrest, former Turing CEO Ron Tilles reckons with the past

While Martin Shkreli smirked his way through a public securities fraud investigation, Ron Tilles became interim CEO of Turing Pharmaceuticals, ready or not. Here’s his story.

By Michael Gibney • Nov. 14, 2024

From Mr. Mucus to the Super Bowl, pharma tries offbeat marketing strategies

As the industry’s marketing dollars shift, companies are targeting potential patients in unique ways.

By Amy Baxter • Nov. 13, 2024

Pharma’s grip on cancer R&D is having unintended consequences

A pair of studies paint a complicated picture of funding and missed research opportunities.

By Alexandra Pecci • Nov. 12, 2024

Pfizer and Lilly’s telehealth prescribing platforms draw Senate scrutiny for ‘potential fraud’

As Big Pharma embraces telehealth to sell medicines directly to patients, lawmakers wonder whether the programs skirt anti-kickback rules.

By Kelly Bilodeau • Nov. 12, 2024

Spravato is just the beginning in a new wave of depression meds

Psychiatry is getting more targeted as drugmakers develop a new range of treatments for depression.

By Meagan Parrish • Nov. 11, 2024

What RFK Jr.’s influence could mean for pharma

Past comments hint at the changes Robert F. Kennedy Jr. could make across the various sectors of healthcare. 

By Amy Baxter • Nov. 8, 2024

With Trump victorious, biotech industry’s focus turns to his plans for FDA, FTC

Speculation around pharma dealmaking and the next FDA commissioner has begun.

By Ned Pagliarulo , Ben Fidler • Nov. 8, 2024

Among 2024’s modest M&A action, cancer, immunology and neuroscience deals trickle in

Dealmaking this year has been largely muted, but M&A trends are pointing to the areas where pharma is placing the most emphasis.

By Michael Gibney • Nov. 7, 2024

An RNAi renaissance is creating a new generation of startups

Pioneers like Alnylam Pharmaceuticals have led the RNA interference field for years. Now, a crop of young biotechs is building on that foundation by taking the drugmaking technology in new directions.

By Gwendolyn Wu • Nov. 7, 2024

A diabetes drug, twice rejected, stumbles again — but its developer persists

After multiple rejections, Lexicon Pharmaceuticals is inching toward an FDA decision date next month for its adjunct type 1 diabetes therapy.   

By Amy Baxter • Nov. 6, 2024

CEO with type 1 diabetes works to deliver ‘world’s first’ functional cure

Sernova’s technology helped type 1 diabetes patients achieve insulin independence in early- and mid-stage trials.

By Alexandra Pecci • Nov. 5, 2024

Pharma takes aim at a wily foe — the Epstein-Barr virus

The pernicious and widespread virus has been linked to a range of diseases including MS and long COVID.

By Kelly Bilodeau • Nov. 4, 2024

Pfizer’s quest for market share in the ‘high stakes battleground’ of oral GLP-1s

Pfizer’s second-to-market goals for its oral GLP-1 drugs underscore big opportunities in the space.

By Amy Baxter • Nov. 4, 2024

A sickle cell cure exists. But patients need more than just gene therapy.

Almost a year after two historic approvals, Pfizer is pulling a sickle cell disease treatment from the market, and the outlook for patients feels shakier.

By Alexandra Pecci • Nov. 1, 2024

2024 PharmaVoice 100s: Cancer Care Visionaries

Leaders who envision a world without cancer through oncology innovation.

By Michael Gibney • Nov. 1, 2024

2024 PharmaVoice 100s: Clinical Trial Pros

Experts raising the bar in clinical trial design and collaboration.

By Amy Baxter • Oct. 31, 2024

Big Pharma earnings hang hope on the next generation of blockbusters

Pfizer, J&J, Biogen and Novartis are banking on new products to make up for maturing blockbusters, but future growth is not guaranteed.

By Michael Gibney • Oct. 31, 2024

Backlash builds against Novo’s Catalent takeover

Roche recently joined naysayers who argue the deal threatens competition in the burgeoning weight loss and diabetes drug market.

By Amy Baxter • Oct. 30, 2024

2024 PharmaVoice 100s: Rare Disease Warriors

Pharma pros driving drug development and access for patients with high unmet needs. 

By Meagan Parrish • Oct. 29, 2024

How AZ’s respiratory wins are ramping up for a bigger prize in COPD

As AstraZeneca builds up indications for Fasenra, an ongoing trial will determine whether the respiratory drug can make up for past stumbles in COPD.

By Michael Gibney • Oct. 29, 2024